胞磷胆碱钠胶囊联合尤瑞克林治疗急性脑梗死的效果及对血清Hcy、CRP水平的影响

Efficacy of citicoline sodium capsule combined with urinary kallidinogenase in the treatment of acute cerebral infarction and its impact on serum levels of Hcy and CRP

摘要:

目的 探讨胞磷胆碱钠胶囊联合尤瑞克林治疗急性脑梗死（ACI）的效果及对血清同型半胱氨酸（Hcy）、C-反应蛋白（CRP）水平的影响。方法 选取2020年1月—2023年1月海南医学院第一附属医院收治的120例ACI患者作为研究对象，采用随机数字表法分为观察组和对照组，每组60例。两组均给予常规组治疗，对照组给予尤瑞克林，观察组在对照组基础上口服胞磷胆碱钠胶囊。比较两组临床疗效，评估其美国国立卫生研究院卒中量表（NIHSS）、日常生活能力量表（ADL），检测两组脑血管相关指标及血清Hcy、CRP水平，观察记录两组不良发生情况。结果 观察组总有效率高于对照组（P <0.05）。观察组治疗前后NIHSS评分的差值高于对照组（P <0.05），ADL评分的下降程度高于对照组（P <0.05）。观察组治疗前后脑血管血流速度、血流量、脑容量下降程度高于对照组（P <0.05）。观察组治疗前后血清Hcy、CRP的差值高于对照组（P <0.05）。观察组与对照组不良反应总发生率比较，差异无统计学意义（P <0.05）。结论 胞磷胆碱钠胶囊联合尤瑞克林治疗ACI临床疗效显著，可有效改善患者神经功能缺损症状和日常生活能力，同时显著改善患者脑血管血流速度、血流量、脑容量及血清Hcy、CRP水平，且安全性较高。

Abstract:

Objective To investigate the efficacy of citicoline sodium capsule combined with urinary kallidinogenase in the treatment of acute cerebral infarction (ACI) and its impact on serum levels of homocysteine (Hcy) and C-reactive protein (CRP).Methods A total of 120 ACI patients admitted to our hospital from January 2020 to January 2023 were selected and randomly divided into an observation group and a control group using the random number table method, with 60 patients in each group. Both groups were given routine treatment, and the control group was given urinary kallidinogenase while the observation group was subject to combined citicoline sodium capsule and urinary kallidinogenase. The clinical efficacy was compared between the two groups. The patients were evaluated with the National Institutes of Health Stroke Scale (NIHSS) and Activity of Daily Living Scale (ADL). The parameters of the cerebral vessels and serum levels of Hcy and CRP levels were measured in both groups. Finally, the incidence of adverse events was observed and analyzed in both groups.Results The overall effective rate of the observation group was higher than that of the control group (P < 0.05). The difference of the NIHSS scores before and after the treatment in the observation group was lower than that in the control group (P < 0.05), while the difference of the ADL scores before and after the treatment in the observation group was higher than that in the control group (P < 0.05). The decreases in cerebral blood flow velocity, cerebral blood flow and cerebral blood volume in the observation group before and after the treatment were greater than those in the control group (P < 0.05). The differences of the serum levels of Hcy and CRP before and after the treatment in the observation group were higher than those in the control group (P < 0.05). There was no statistically significant difference in the overall incidence of adverse reactions between the observation group and the control group (P < 0.05).Conclusions The combination of citicoline sodium capsule and urinary kallidinogenase has significant clinical efficacy in the treatment of ACI. It effectively improves neurological deficits and activities of daily living of patients, and significantly increases the cerebral blood flow velocity, cerebral blood flow and cerebral blood volume as well as the serum levels of Hcy and CRP with few safety concerns.